

The Directors
Amryt Pharma plc
Dept 920a
196 High Road
Wood Green
London N22 8HH
United Kingdom

Re: **Amryt Pharma plc – Consent Letter**

Dear Sirs:

We, Haug Partners LLP, refer to the admission document of Amryt Pharma plc (the “**Company**”) dated 27 August 2019 relating to, among other things, the acquisition of Aegerion Pharmaceuticals, Inc. (“**Aegerion**”), the scheme of arrangement, and the applications for admission of the entire issued share capital of a new holding company of the Company to AIM and the Euronext Growth Market (the “**Admission Document**”).

We hereby give our consent to the inclusion in the Admission Document of our patent report relating to Aegerion dated 22 August 2019 and the references to our name generally in the form and context in which they are included, as shown in the enclosed proof of the Admission Document initialed by us for the purpose of identification.

Our consent is required by Annex 1 item 1.3 of Commission Delegated Regulation (EU) No 2019/980 as applied by paragraph (a) of Schedule Two to the AIM Rules for Companies and paragraph (a) of Schedule Two of Chapter 5 of Part II of the Euronext Growth Markets Rule Book, and is given for the purpose of complying with those provisions and for no other purpose.

Yours faithfully,



Russell A. Garman, Ph.D.
Partner

Haug Partners LLP